RxDoctor Payments Data

Brian Borsook, MD

Family Medicine · Torrance, CANPI 1437165370

Payments from drug & device makers

$11,363in general payments, 2019–2025

Across 486 payments — averaging $23.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Biohaven Pharmaceuticals, Inc.$1K
  • AbbVie$964
  • Novo Nordisk$824
  • Lilly USA, LLC$556
  • Boehringer Ingelheim$547
  • plus $5K from 39 others

What the payments were for

  • Consulting fees$1,20011%
  • Food & beverage$10,14389%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,363 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$65,361
Medicare patients
151
Services billed
846

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban70$102,081
FarxigaDapagliflozin Propanediol59$60,142
OzempicSemaglutide36$58,281
JardianceEmpagliflozin32$45,215
TrulicityDulaglutide22$44,890
JanuviaSitagliptin Phosphate23$38,002
Bydureon BciseExenatide Microspheres12$27,348
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$21,535
XareltoRivaroxaban13$19,819
Aimovig AutoinjectorErenumab-Aooe13$18,858
LinzessLinaclotide12$18,388
RestasisCyclosporine16$12,409
RybelsusSemaglutide12$11,421
MyrbetriqMirabegron13$11,243
Wixela InhubFluticasone Propion/Salmeterol21$7,042

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$424$102,08170 claims
Novo NordiskOzempic, Rybelsus$824$69,70248 claims
AstraZenecaFarxiga$1,789$60,14259 claims
Boehringer IngelheimJardiance$547$45,21532 claims
Lilly USA, LLCTrulicity$556$44,89022 claims
MerckJanuvia$500$38,00223 claims
AbbVieLinzess, Restasis$964$30,79828 claims
GSKTrelegy Ellipta$267$21,53519 claims
Johnson & JohnsonXarelto$495$19,81913 claims
Astellas Pharma US IncMyrbetriq$349$11,24313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Torrance

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →